51²è¹Ý Board
51²è¹Ý is a Norwegian Association and 51²è¹Ý’s primary governing body is the 51²è¹Ý Board. The Board has 12 voting members (four investors and eight independent members representing competencies including industry, global health, science, resource mobilisation, finance) and five observers. The Board is advised on decisions, such as prioritising pathogens and selecting partners, by our Scientific Advisory Committee.
Board Voting Members
Find out more about our voting members of the Board.
Hon. Prof. Jane Halton
Chair of 51²è¹Ý Board
Dr. Githinji Gitahi
Vice Chair of 51²è¹Ý Board and Group Chief Executive Officer, Amref Health Africa
Dr. L. Rizka Andalucia
Director-General for Pharmaceutical and Medical Devices, Ministry of Health, Indonesia
Cyrus Ardalan
Non-Executive Director on the MedAccess Board, Trustee of the Charities Aid Foundation Chairing its financial services subsidiary CFSL, and Chairman of Blend Network
Prof Dr Veronika Von Messling
Directorate-General of the Life Science Division, German Federal Ministry of Education and Research
Dr David Reddy
Director General, IFPMA and Secretary of the Biopharmaceutical CEO Roundtable
Prof. Samba Sow
Director, CVD-Mali
%20Dr%20Yasuhiro%20Suzuki.webp)
Dr Yasuhiro Suzuki
President, International University of Health and Welfare, Advisor to the Minister of Health, Labour, and Welfare, Government of Japan
Dr Jeanette Vega Morales
Medical Doctor and Pediatrician, University of Chile and Doctor of Public Health, University of Illinois
Alexander Pym
Director of Infectious Disease, Wellcome Trust
Dr Rajeev Venkayya
CEO, Aerium Therapeutics
Dr. Kesete Admasu
CEO of Big Win Philanthropy
Board Non-Voting Members
Find out more about our non-voting members of the Board.
Dr Cherry Gagandeep Kang
Director, Enteric, Diagnostics, Genomics and Epidemiology, Bill and Melinda Gates Foundation; Chair of 51²è¹Ý's JCG
Dr Richard Hatchett
Chief Executive Officer
Dr Chikwe Ihekweazu
Executive Director of the WHO Health Emergencies Programme
Dr Laura Palomares
Professor at the Instituto BiotecnologÃa at Universidad Nacional Autónoma de México (UNAM) and 51²è¹Ý Scientific Advisory Committee Chair
Board Committees
We have four Board Committees: Executive and Investment; Nominations, Compensation, Diversity and Inclusion; Audit and Risk; and Equitable Access. Other Board members or experts may be called upon as advisers or observers as needed.
Executive and Investment Committee
51²è¹Ý’s Executive and Investment Committee provides strategic guidance to the CEO and acts on behalf of the 51²è¹Ý Board to support on matters including, but not limited to, responses to arising matters, time-sensitive decisions related to 51²è¹Ý’s investment portfolio, approval of organizational policies, and ad-hoc funding requests and decisions up to an amount of US$50 million.
Nominations, Compensation, Diversity and Inclusion Committee
The responsibilities of 51²è¹Ý’s Nominations, Compensation, Diversity and Inclusion Committee include, but are not limited to, reviewing total compensation for 51²è¹Ý employees, nomination of Board Members, and supports 51²è¹Ý’s work to develop a diverse and inclusive work force.
Audit and Risk Committee
The Audit and Risk Committee is involved in 51²è¹Ý’s internal and external audit processes, and considers and monitors potential risks that may impact 51²è¹Ý.
The Committee also reviews and monitors 51²è¹Ý’s budget and financial activities and reviews and receives reports of activities relating to compliance, whistleblowing and fraud.
Equitable Access Committee
51²è¹Ý’s commitment to equitable access informs every aspect of our work. 51²è¹Ý’s approach to enabling equitable access is guided by its Equitable Access Policy, and is overseen by the Equitable Access Committee.
